Recent studies have implicated that the transdifferentiation of adenocarcinoma into treatment-emergent neuroendocrine PCa (t-NEPC) is a critical mechanism of drug resistance after treatment with the second generation AR antagonists [17–21]. Here, AR is linked to adenocarcinoma.